• Source: Traneurocin

Traneurocin (developmental code name NA-831), also known as cycloprolylglycine (CPG), is a racetam-like drug which is under development for the treatment of COVID-19, Alzheimer's disease, fragile X syndrome, Rett syndrome, major depressive disorder, and other neurological disorders. In the case of COVID-19, it is specifically being developed for treatment of COVID-19-induced neuropathy.




Pharmacology






= Pharmacodynamics

=
The mechanism of action of traneurocin is either unknown or undisclosed. However, it has been described as acting as a positive allosteric modulator of the AMPA receptor and has been found to increase brain-derived neurotrophic factor (BDNF) levels. It has also been found to act as a positive allosteric modulator of the GABAA receptor. The drug is described as having neuroprotective, neurogenesis-stimulating, and pro-cognitive or nootropic effects. It has also been reported to have antihypoxic and anxiolytic properties.




= Pharmacokinetics

=
It is known to be an endogenous compound present at micromolar concentrations in the rat brain and readily crosses the blood–brain barrier.




Chemistry


Chemically, traneurocin is a synthetic cyclized dipeptide composed of the amino acids glycine and proline.




Clinical trials


As of September 2024, traneurocin is in phase 3 clinical trials for COVID-19, phase 2 clinical trials for Alzheimer's disease, fragile X syndrome, and Rett syndrome, and phase 1 clinical trials for major depressive disorder. No development has been reported for treatment of other neurological disorders. Traneurocin was first developed, under the name cycloprolylglycine (CPG), in Russia in 1991 as a drug related structurally and pharmacologically to piracetam. Cycloprolylglycine is also related to and known to be the major metabolite of omberacetam (Noopept).
Another drug, vineurocin (NA-704), is also being developed for treatment of Alzheimer's disease. This drug is described as a recombinant growth hormone with neuroprotective and neurogenic effects.




See also


List of Russian drugs




References






External links


NeuroActiva - Pipeline (Including Traneurocin)
NA-831 - BioMed
NA-831 (traneurocin) - AlzForum

Kata Kunci Pencarian:

• Traneurocin
• N-Phenylacetyl-L-prolylglycine ethyl ester
• Cyclic glycine-proline
• List of Russian drugs
• CPG
• AMPA receptor
• AMPA receptor positive allosteric modulator
• List of investigational antidepressants